Immunovant (IMVT) Accumulated Expenses (2018 - 2026)
Immunovant's (IMVT) quarterly Accumulated Expenses came in at $96.6 million in Q1 2026, up 90.42% YoY from $50.7 million in Q1 2025, and up 67.65% on a QoQ basis from $57.6 million in Q4 2025.
Immunovant (IMVT) Accumulated Expenses (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Accumulated Expenses data on file, last reported at $96.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 90.42% year-over-year to $96.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $96.6 million (up 90.42% YoY) and the FY2026 annual result came in at $96.6 million, up 90.42% from the prior year.
- Accumulated Expenses rose to $96.6 million in Q1 2026, from $57.6 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $96.6 million in Q1 2026 to a low of $19.0 million in Q2 2022.
- A 5-year average of $40.8 million and a median of $40.4 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses dropped 17.16% — and 2026, when it jumped 90.42%.
- Tracing IMVT's Accumulated Expenses over 5 years: stood at $26.0 million in 2022, then advanced by 7.05% to $27.9 million in 2023, then surged by 73.84% to $48.5 million in 2024, then grew by 18.91% to $57.6 million in 2025, then surged by 67.65% to $96.6 million in 2026.
- The last three Accumulated Expenses figures came in at $96.6 million (Q1 2026), $57.6 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 106.96 Mn |
| Mar 31, 2026 | 96.63 Mn |
| Dec 31, 2025 | 57.64 Mn |
| Sep 30, 2025 | 56.34 Mn |
| Jun 30, 2025 | 45.06 Mn |
| Mar 31, 2025 | 50.75 Mn |
| Dec 31, 2024 | 48.48 Mn |
| Sep 30, 2024 | 45.88 Mn |
| Jun 30, 2024 | 33.91 Mn |
| Mar 31, 2024 | 41.30 Mn |
| Dec 31, 2023 | 27.89 Mn |
| Sep 30, 2023 | 32.13 Mn |
| Jun 30, 2023 | 23.98 Mn |
| Mar 31, 2023 | 40.42 Mn |
| Dec 31, 2022 | 26.05 Mn |
| Sep 30, 2022 | 23.14 Mn |
| Jun 30, 2022 | 19.01 Mn |
| Mar 31, 2022 | 24.58 Mn |
| Dec 31, 2021 | 31.45 Mn |
| Sep 30, 2021 | 23.06 Mn |